DSGN News

In a turbulent week for the IPO market, 17 IPOs and 20 SPACs went public, and one company postponed, defense contractor Leonardo DRS (DRS). While returns cooled off, with just over half of the week’s IPOs finishing below issue, there were a few bright spots, led by biotechs Design Therapeutics (DSGN) and Ikena Oncology...read more

Design Therapeutics, a preclinical biotech developing small molecule therapies for genetic diseases, raised $240 million by offering 12 million shares at $20, the high end of the range of $18 to $20. Design Therapeutics is developing novel small-molecule therapies, called gene targeted chimeras (GeneTACs), that are designed to be disease-modifying and target the underlying...read more

Design Therapeutics, a preclinical biotech developing small molecule therapies for genetic diseases, announced terms for its IPO on Monday. The Carlsbad, CA-based company plans to raise $228 million by offering 12 million shares at a price range of $18 to $20. At the midpoint of the proposed range, Design Therapeutics would command a fully diluted market value of $1.1 billion. ...read more

Updated Monday, 3/22. 15 IPOs are currently scheduled to raise $5.7 billion in the week ahead as IPO activity continues to pick up. The diverse group spans six sectors and includes cleaning products, defense technology, low-cost TVs, crafting machines, and more. Cleaning products maker Diversey Holdings (DSEY) plans to raise $900 million at a $5...read more